Strides Pharma Q1 FY27: Revenue +13%, PAT +57% details

What Strides Pharma reported for Q1 FY27

Strides Pharma Science Ltd reported a steady start to FY27, with consolidated revenue rising 13% year-on-year (YoY) even as it flagged higher freight and operating costs linked to geopolitical disruptions. For the quarter ended June 30, 2026 (Q1 FY27), the company’s consolidated revenue from operations increased to ₹1,265.41 crore. Reported profit after tax (PAT) jumped 56.7% YoY to ₹165.49 crore, supported by an exceptional gain tied to the Pivot Path transaction.

The company presented its Q1 FY27 earnings on July 31, 2026, and another results update noted that Q1 FY 2026-27 results were announced on August 1, 2026. Alongside the financial release, Strides also scheduled an earnings conference call for July 31, 2026 at 5:00 PM IST to discuss the unaudited results. The quarter’s headline numbers show a clear split between resilient revenue growth and a more mixed picture on operating margins.

Consolidated revenue growth and total income

Consolidated total revenue reached ₹1,265.40 crore in Q1 FY27 (₹12,654 million), up from ₹1,119.70 crore in Q1 FY26 (₹11,197 million). Another disclosure showed revenue from operations at ₹1,265.41 crore (₹12,654.07 million) for the quarter. Total income for the period was reported at ₹1,270.30 crore.

On a sequential basis, Strides reported a 4.6% quarter-on-quarter (QoQ) decline in consolidated revenues for Q1 FY27. Total income was ₹1,270.30 crore compared with ₹1,331.60 crore in the previous quarter (Q4 FY26). Despite the QoQ dip, the company recorded a 12.6% YoY increase versus Q1 FY26, when total income stood at ₹1,128.32 crore.

Segment performance: US steady, Ex-US drives growth

The quarter’s geographic mix showed a stronger contribution from markets outside the US. Ex-US markets revenue grew 17% YoY to ₹587.50 crore (₹5,875 million). The company attributed the overall top-line momentum to this expansion in international markets.

The US business remained steady at ₹628.20 crore (₹6,282 million), growing 4% YoY. However, the US number showed a slight sequential decline from Q4 FY26’s ₹646.70 crore (₹6,467 million). This combination meant Ex-US growth provided the key lift, while the US stayed broadly muted.

Profit surge and the Pivot Path one-time gain

Strides reported PAT rose 56.7% YoY to ₹165.49 crore (₹1,655 million) in Q1 FY27. The company linked the sharp jump in reported profitability to a one-time gain from divesting a majority stake in Pivot Path. One disclosure described the divestment as unlocking ₹100 crore (₹1,000 million) of value.

A separate results summary quantified the exceptional gain at ₹74.21 crore from the Pivot Path stake dilution. While the precise exceptional amount is presented differently across the cited updates, the common point is that the reported PAT increase was materially supported by a non-recurring gain related to Pivot Path.

The company also reported operational PAT of ₹123.10 crore (₹1,231 million), up 8% YoY from ₹114.00 crore (₹1,140 million). Operational earnings per share (EPS) was stated at ₹13.4, compared with ₹12.4 in Q1 FY26. Reported EPS was indicated at about ₹17.0, and another quarterly snapshot put EPS at 17.02 for Q1 FY27.

Margins: gross margin improved, EBITDA margin softened

Strides reported gross margins expanded to 60.9% in Q1 FY27 from 60.3% a year earlier, an improvement of 60 basis points. In absolute terms, the gross margin rose 14% YoY to ₹770.20 crore (₹7,702 million). This came even as the company cited elevated operating and freight costs.

EBITDA for the quarter was reported at ₹229.80 crore (₹2,298 million), up 5.4% YoY. But EBITDA margin compressed to 18.2% from 19.5% in the prior-year quarter, a decline of 130 basis points. Management also cited an approximately ₹13.10 crore (₹131 million) impact from freight and operating costs due to geopolitical disruptions.

Quarter-on-quarter snapshot from the reported table

The company’s quarterly comparison data highlighted that expenses were down 3.9% QoQ and up 13.5% YoY. Profit before tax (PBT) was listed at ₹200.90 crore in Q1 FY27, versus ₹146.60 crore in Q4 FY26 and ₹121.94 crore in Q1 FY26.

Profit after tax in that table was shown at ₹165.49 crore for Q1 FY27, compared with ₹129.28 crore in Q4 FY26 and ₹105.59 crore in Q1 FY26. This implies PAT growth of 28.0% QoQ and 56.7% YoY in the same dataset. EPS was shown at 17.02 in Q1 FY27, compared with 13.77 in Q4 FY26 and 10.81 in Q1 FY26.

Standalone performance: profit up 16% YoY

Separately, Strides Pharma Science reported a 16% YoY rise in standalone net profit for the quarter ended June 30, 2026, to ₹21.13 crore (₹2,113.26 lakh). Standalone total income from operations increased to ₹208.71 crore (₹20,870.93 lakh), from ₹196.64 crore (₹19,664.02 lakh) in the corresponding period last year.

The standalone numbers indicate top-line resilience alongside profitability improvement in that segment, even as the consolidated picture included both operating pressures and the impact of exceptional items.

Dividend record date and investor communication

Strides fixed Friday, July 31, 2026 as the record date to determine shareholder eligibility for a final dividend of ₹5 per equity share. The company also held its earnings conference call on July 31, 2026 to discuss the unaudited results for the quarter ended June 30, 2026.

These corporate actions and investor updates arrived alongside the quarterly results that showed solid revenue growth, improving gross margins, and a reported PAT boosted by the Pivot Path transaction.

Key numbers at a glance (Q1 FY27)

Market impact: what the results signal

The Q1 FY27 release shows Strides was able to grow consolidated revenue by 13% YoY, with Ex-US markets contributing a large part of the momentum through 17% YoY growth. At the same time, the company acknowledged cost pressures, including a stated impact of about ₹13.10 crore from freight and operating costs due to geopolitical disruptions.

The margin bridge in the numbers is important: gross margin percentage improved slightly, but EBITDA margin compressed. That suggests price and product mix and/or efficiency helped at the gross level, while overheads and freight costs weighed on operating profitability. Reported PAT, however, increased sharply because of the one-time gain from the Pivot Path stake divestment.

Analysis: separating operating performance from exceptional items

Operational metrics point to more modest improvement than the reported bottom line. Operational PAT rose 8% YoY to ₹123.10 crore, and operational EPS was ₹13.4. In comparison, reported PAT of ₹165.49 crore reflects the impact of exceptional income associated with Pivot Path.

For investors tracking quarterly consistency, the QoQ decline in total income to ₹1,270.30 crore from ₹1,331.60 crore is also a key datapoint, particularly alongside the sequential softness in US revenue from ₹646.70 crore to ₹628.20 crore. The company’s commentary on elevated freight and operating costs provides context for the EBITDA margin compression to 18.2%.

Conclusion

Strides Pharma’s Q1 FY27 results combined 13% YoY consolidated revenue growth with a 56.7% jump in reported PAT to ₹165.49 crore, helped by a one-time gain linked to Pivot Path. Ex-US markets growth of 17% YoY was the standout driver, while the US business delivered 4% YoY growth but eased sequentially. Investors will watch how margins evolve after the quarter’s cited freight and operating cost impact, alongside any further updates following the July 31, 2026 earnings call and the ₹5 per share dividend record date.